Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

ition patients to open-label anticoagulation at the end of the trial, which resulted in a low and evenly distributed number of events post-discontinuation of study therapy. In the 30 days following the transition, the number of patients experiencing stroke or SEE was the same in all three treatment groups (n=7), while major bleeding occurred in 11 patients in the warfarin group compared to 10 and 18 patients in the edoxaban 60 mg and 30 mg treatment arms, respectively. These results demonstrate that the transition plan was effective in preventing undue risk of excessive stroke / SEE for edoxaban-treated subjects transitioning to a vitamin K antagonist (VKA) or a novel oral anticoagulant.2

About Atrial Fibrillation

Atrial fibrillation (AF) is a condition in which the heartbeat is rapid and irregular, and can potentially lead to a stroke. AF is a common condition, affecting approximately 1-2% of people in developed nations.3 Stroke is the second most common cause of death worldwide, responsible for approximately 6.2 million deaths each year.4 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.3 Strokes due to AF are nearly twice as likely to be fatal than strokes in patients without AF5 and have poorer prognosis than non-AF related strokes with a 50% increased risk of remaining disabled at three months.6

About Edoxaban

Edoxaban is an investigational, oral, once-daily anticoagulant that specifically and reversibly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.7 The global edoxaban clinical trial program includes two phase 3 clinical trials, Hokusai-VTE8 and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation)1,2, which are evaluating edoxaban, administered once-daily, for tre
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Henry Schein, Inc. (NASDAQ: ... services to office-based practitioners, announced today that Ferdinand ... the CL King 9th Annual Best Ideas Conference 2011. The ... New York City. Henry Schein,s presentation is ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, reported positive data from a recently ... dual inhibitor of the sodium glucose transporters 1 and ... effects on multiple parameters of glycemic control and cardiovascular ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 3LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 4
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Being in good shape seems ... They looked at data from more than 57,000 Americans, ... treadmill tests between 1991 and 2009. Those in the ... having high blood pressure at the start of the study, ... levels of fitness. Of the more than 8,000 people ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... Hill, IL (PRWEB) December 17, 2014 ... 2015 Awards celebrate the best of the best in ... The award is only given to communities and agencies ... through the SeniorAdvisor.com site. Of the nearly 100,000 providers ... this award. Winners of the SeniorAdvisor.com Best of 2015 ...
Breaking Medicine News(10 mins):Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... analysis of strains responsible for common cold and other ... the virusROCKVILLE, Md., Feb. 12 A team of ... University of Maryland School of Medicine and ... they have sequenced and analyzed the genomes of all ...
... Today, the Medicaid Health Plans of America (MHPA) ... Medicaid health plans, applauded House and Senate negotiators who ... Reinvestment Act Conference Report that will maintain coverage for ... in this agreement will allow states to continue coverage ...
... Tobacco Prevention CampaignsWASHINGTON, Feb. 12 The ... Myers, President, Campaign for Tobacco-Free Kids:(Logo: ... provide powerful new evidence that tobacco marketing ... campaigns prevent smoking. These studies send ...
... in Sweden doesn,t transfer to U.S., study finds , , THURSDAY, ... whether smokeless tobacco can help smokers quit cigarettes, contends a ... quit smoking by using snus, a form of moist, powdered ... more popular among male smokers, and Swedish men have higher ...
... for treatments deemed safe and effective. The stimulus ... set by a new bureaucracy, the Federal Coordinating Council ... a U.K. board discussed in Tom Daschle,s book, ... treatments using a formula that divides the cost of ...
... Venture Capitalists to Identify Investment Opportunities in the Multi-Billion ... N.Y., Feb. 12 The equity markets and the ... young medical device companies and private equity investors to ... For venture capitalists, the "New Economy " ...
Cached Medicine News:Health News:Complete Genomes of All Known Human Rhinoviruses are Published 2Health News:Complete Genomes of All Known Human Rhinoviruses are Published 3Health News:Medicaid Health Plans of America Lauds Stimulus Bill's Conference Agreement Which Provides $90 Billion in Medicaid Relief for Nation's Most Vulnerable Citizens 2Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 2Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 3Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 4Health News:Smokeless Tobacco May Not Help Smokers Quit 2Health News:MedTech Investing Conference (8th Annual) May 6-7, 2009 2Health News:MedTech Investing Conference (8th Annual) May 6-7, 2009 3
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Jaguar Lumbar I/F Cage system is a ... separate the mechanical and biologic functions of ... Lumbar I/F Cage provides a device designed ... and uses autologous cancellous bone, the best ...
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
Medicine Products: